Traduction de «develop the strategic decision » (Néerlandais → Français) :

The implementation of the new organisation chart as envisaged for the start of 2009 requires the P&O Service to develop a definition of its future role in terms of the expectations from the 3 Directorates-General and other departments and services, to implement the 1 % reduction imposed for personnel expenditure and to further develop the strategic decision to convert the FAMHP into a “learning organisation”.
The implementation of the new organisation chart as envisaged for the start of 2009 requires the P&O Service to develop a definition of its future role in terms of the expectations from the 3 Directorates-General and other departments and services, to implement the 1 % reduction imposed for personnel expenditure and to further develop the strategic decision to convert the FAMHP into a “learning organisation”.

presented to the Delphi panel. A consensus appeared from the first round that citizens should be involved for strategic decisions (setting budgetary priority) and patients for more operational decisions (e.g. product reimbursement decision linked to a specific disease).
that citizens should be involved for strategic decisions (setting budgetary priority) and patients for more operational decisions (e.g. product reimbursement decision linked to a specific disease).

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

“Comparative cost analysis: Community based services as an alternative to institutions" , tender no. VT/2005/021, Official Journal on 22 June 2005 N° 2005/S 119-117014 [http ...]
K. ; Paul R (Hrsg.) : Health Promoting Hospitals in Practice: Developing Projects and Networks – Conrad, Gamburg Inclusion Europe, Included in Society (2003-2004), projet réalisé dans le contexte du Fonds social européen ( [http ...]

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

Marie-Claire Hamès, regentes in sociale en huishoudelijke economie, leerkracht, lid van het Raadgevend Comité van het FAVV voor de Duitse Gemeenschap Siska Pottie, adviseur voedingsbeleid, FEVIA Myriam Lambillon, coördinatrice van de ’ ‘Union des Agricultrices Wallonnes’ Ingrid Vanhaevre, directeur ‘Strategic and Policy Development’, OIVO
Marie-Claire Hamès, régente en économie sociale et familiale, enseignante et membre du comité consultatif de l’AFSCA pour la Communauté germanophone Siska Pottie, Conseillère «politique alimentaire», FEVIA Myriam Lambillon, Coordinatrice de l’Union des Agricultrices Wallonnes Ingrid Vanhaevre, Directeur ‘Strategic and Policy Development’, CRIOC

Marie-Claire Hamès, regentes in sociale en huishoudelijke economie, leerkracht, lid van het Raadgevend Comité van het FAVV voor de Duitstalige Gemeenschap Siska Pottie, adviseur voedingsbeleid, FEVIA Myriam Lambillon, coördinatrice van de ’ ‘Union des Agricultrices Wallonnes’ Ingrid Vanhaevre, directeur ‘Strategic and Policy Development’, OIVO
Marie-Claire Hamès, régente en économie sociale et familiale, enseignante et membre du Comité Consultatif de l’AFSCA pour la Communauté germanophone Siska Pottie, conseillère ‘politique alimentaire’ chez FEVIA Myriam Lambillon, coordinatrice de l’Union des Agricultrices Wallonnes Ingrid Vanhaevre, directeur ‘Strategic and Policy Development’ au CRIOC

De definitie van het Amerikaanse Institute of Medicine geeft de essentie van het begrip „praktijkrichtlijn‰ gevat weer: „systematically developed statements to assist practitioners and patient decisions about appropriate health care for specific clinical circumstances‰.
LÊInstitute of Medicine des Etats-Unis présente lÊessence du concept de „recommandation de bonne pratique‰ en le définissant comme suit : „systematically developed statements to assist practitioners and patient decisions about appropriate health care for specific clinical circumstances‰.

The role of the Central Working Group is to take decisions together with the Chief Executive Officer regarding the development of the FAMHP and to set priorities.
The role of the Central Working Group is to take decisions together with the Chief Executive Officer regarding the development of the FAMHP and to set priorities.